Legend Biotech Corp ADR (NASDAQ: LEGN) on Tuesday, soared 0.35% from the previous trading day, before settling in for the closing price of $40.04. Within the past 52 weeks, LEGN’s price has moved between $38.60 and $70.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 50.60%. The company achieved an average annual earnings per share of 42.49%. With a float of $181.45 million, this company’s outstanding shares have now reached $181.91 million.
The extent of productivity of a business whose workforce counts for 1826 workers is very important to gauge. In terms of profitability, gross margin is 56.67%, operating margin of -76.29%, and the pretax margin is -62.95%.
Legend Biotech Corp ADR (LEGN) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Legend Biotech Corp ADR is 0.94%, while institutional ownership is 50.17%. The most recent insider transaction that took place on Sep 25 ’24, was worth 66,326. Before that another transaction happened on Sep 20 ’24, when Company’s Officer proposed sale 90,060 for $48.91, making the entire transaction worth $4,405,003.
Legend Biotech Corp ADR (LEGN) Performance Highlights and Predictions
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.34 earnings per share (EPS) for the period topping the consensus outlook (set at -0.68) by 0.34. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.49% per share during the next fiscal year.
Legend Biotech Corp ADR (NASDAQ: LEGN) Trading Performance Indicators
Legend Biotech Corp ADR (LEGN) is currently performing well based on its current performance indicators. A quick ratio of 4.78 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.57, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -0.43 in one year’s time.
Technical Analysis of Legend Biotech Corp ADR (LEGN)
The latest stats from [Legend Biotech Corp ADR, LEGN] show that its last 5-days average volume of 2.13 million was superior to 1.09 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 14.37%. Additionally, its Average True Range was 2.35.
During the past 100 days, Legend Biotech Corp ADR’s (LEGN) raw stochastic average was set at 6.30%, which indicates a significant decrease from 15.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.07% in the past 14 days, which was lower than the 48.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $46.86, while its 200-day Moving Average is $51.44. Now, the first resistance to watch is $41.72. This is followed by the second major resistance level at $43.26. The third major resistance level sits at $44.65. If the price goes on to break the first support level at $38.79, it is likely to go to the next support level at $37.40. Assuming the price breaks the second support level, the third support level stands at $35.86.
Legend Biotech Corp ADR (NASDAQ: LEGN) Key Stats
Market capitalization of the company is 7.36 billion based on 182,305K outstanding shares. Right now, sales total 285,140 K and income totals -518,250 K. The company made 186,520 K in profit during its latest quarter, and -18,200 K in sales during its previous quarter.
